Emergent BioSolutions Inc. (EBS)
Market Cap | 392.49M |
Revenue (ttm) | 1.19B |
Net Income (ttm) | -565.20M |
Shares Out | 52.40M |
EPS (ttm) | -10.94 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 4,410,150 |
Open | 7.28 |
Previous Close | 7.06 |
Day's Range | 7.24 - 8.29 |
52-Week Range | 1.42 - 8.29 |
Beta | 1.64 |
Analysts | Buy |
Price Target | 8.00 (+6.81%) |
Earnings Date | Aug 6, 2024 |
About EBS
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of d... [Read more]
Full Company ProfileFinancial Performance
In 2023, EBS's revenue was $1.05 billion, a decrease of -6.10% compared to the previous year's $1.12 billion. Losses were -$760.50 million, 259.4% more than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for EBS stock is "Buy." The 12-month stock price forecast is $8.0, which is an increase of 6.81% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/t/n/biotech7-2507160.jpg)
Why Is Vaccine Maker Emergent BioSolutions Stock Trading Higher On Tuesday?
Nvidia Corp NVDA is trading lower Tuesday amid reports that the company faces antitrust charges from French regulators.
![](https://cdn.snapi.dev/images/v1/z/1/press1-2506621.jpg)
Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than $250 million in contract modifications from the Administration for...
![](https://cdn.snapi.dev/images/v1/1/l/press9-2506384.jpg)
Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than $250 million in contract modifications from the Administration for...
![](https://cdn.snapi.dev/images/v1/8/x/press2-2487589.jpg)
Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million
GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has entered into a definitive agreement to sell its drug product facility in Baltimo...
![](https://cdn.snapi.dev/images/v1/a/t/press18-2466072.jpg)
Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day
GAITHERSBURG, Md., June 06, 2024 (GLOBE NEWSWIRE) -- In recognition of National Naloxone Awareness Day, Emergent BioSolutions Inc. (NYSE: EBS) is highlighting its ongoing efforts to combat the opioid ...
![](https://cdn.snapi.dev/images/v1/p/c/press16-2423734.jpg)
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024
GAITHERSBURG, Md., May 10, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2024 Annual Meeting of Stockholders will be held in a virtual-only format via live a...
![](https://cdn.snapi.dev/images/v1/l/8/biotech4-2404672.jpg)
Narcan-Maker Emergent BioSolutions to Cut 300 Jobs, Close Facilities
Emergent BioSolutions is closing several manufacturing facilities and cutting hundreds of jobs as part of a restructuring as the company narrows its focus on products, including Narcan nasal spray.
![](https://cdn.snapi.dev/images/v1/6/u/press20-2404526.jpg)
Emergent BioSolutions Reports First Quarter 2024 Financial Results
GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2024.
![](https://cdn.snapi.dev/images/v1/s/z/m02d20210730t2i1570481752w940f-2404497.jpg)
Emergent BioSolutions to lay off about 300 employees
Emergent BioSolutions said on Wednesday that it would cut about 300 jobs across all areas of the company and shut down several manufacturing facilities as part of a restructuring plan.
![](https://cdn.snapi.dev/images/v1/y/l/press5-2404262.jpg)
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced the next phase of its new operational plan that consolidates operations, closes several manufactur...
![](https://cdn.snapi.dev/images/v1/u/i/press15-2403389.jpg)
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the results of a new national public opinion survey showing that more than 90 percent of Amer...
![](https://cdn.snapi.dev/images/v1/t/0/press20-2401483.jpg)
Emergent BioSolutions Announces Amendment to its Existing Credit Facility
GAITHERSBURG, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that it has entered into a “Consent, Waiver and Seventh Amendment” to its existing credit facilit...
![](https://cdn.snapi.dev/images/v1/j/y/conf13-2382895.jpg)
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial res...
![](https://cdn.snapi.dev/images/v1/q/h/press20-2346054.jpg)
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
GAITHERSBURG, Md., March 28, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) remains committed to fighting the ongoing opioid crisis by broadening access to, and awareness of, NARCAN® ...
![](https://cdn.snapi.dev/images/v1/i/k/press18-2339546.jpg)
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
GAITHERSBURG, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has listed “No Action Indicated” or NAI status c...
![](https://cdn.snapi.dev/images/v1/4/h/press7-2311930.jpg)
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
GAITHERSBURG, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2023.
![](https://cdn.snapi.dev/images/v1/h/v/conf9-2300669.jpg)
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
GAITHERSBURG, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, March 6, 2024, at 5:00 pm eastern time to discuss the financial re...
![](https://cdn.snapi.dev/images/v1/a/l/press8-2285502.jpg)
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a global company providing solutions that address public health threats and delivering life-extending produ...
![](https://cdn.snapi.dev/images/v1/r/v/conf1-2221981.jpg)
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
GAITHERSBURG, Md., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a global company providing solutions that address public health threats and brings lifesaving, life-extending pr...
![](https://cdn.snapi.dev/images/v1/1/s/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f7326292fmedical-professional-working-at-a-computer-terminaljpgopresizew400h400-1891287-2208346.jpg)
Emergent BioSolutions stock pulls back, after rallying last week in wake of Biden administration's endorsement of overdose medications
Shares of Emergent BioSolutions Inc. EBS slumped 2.8% in afternoon trading Tuesday, after surging more than 11% over the past two sessions, including Friday's 8.3% rally. The rally to end last week ca...
![](https://cdn.snapi.dev/images/v1/c/6/press2-2173525.jpg)
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
GAITHERSBURG, Md., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administr...
![](https://cdn.snapi.dev/images/v1/c/7/press17-2170606.jpg)
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
GAITHERSBURG, Md., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today confirmed that on November 16, 2023, the New York Stock Exchange (NYSE) sent a notice that the company...
![](https://cdn.snapi.dev/images/v1/x/p/press5-2148504.jpg)
Emergent BioSolutions Reports Third Quarter 2023 Financial Results
GAITHERSBURG, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported selected financial results for the third quarter ended September 30, 2023. The selected finan...
![](https://cdn.snapi.dev/images/v1/k/c/conf9-2129099.jpg)
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
GAITHERSBURG, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) has rescheduled its conference call to Wednesday, November 8, at 5:00 pm eastern time to discuss the financi...
![](https://cdn.snapi.dev/images/v1/o/c/conf11-2110530.jpg)
Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023
GAITHERSBURG, Md., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 2, 2023, at 5:00 pm eastern time to discuss the financial ...